Determining the levels of glycated hemoglobin gives assurance to healthcare practitioners about decision making on the treatment to be prescribed to diabetic patients. Such tests are primarily used for diagnosis and monitoring of hemoglobin A1c levels. Hemoglobin A1c test provides the average amount of patient’s glucose levels in last 2 to 3 months, therefore, it is preferred over other conventionally used blood glucose tests. Due to this reason, medical practitioners are increasingly recommending hemoglobin A1c testing devices over glucose testing devices to diabetic patients which has lead to increased use of hemoglobin A1c testing devices.
This study covers the market analysis for various technologies and end-uses of hemoglobin A1c (HbA1c) testing devices. The stakeholders for this report include manufacturers of hemoglobin A1C testing analyzers, research organizations involved in developing new and innovative technologies for hemoglobin A1c testing devices and the new players who wish to enter this market. The report consists of executive summary, which provides the market snapshot containing the information of segments of hemoglobin A1c testing devices market. This section also includes the comparative analysis of hemoglobin A1c market based on different geographical regions.
The market overview section of this report gives a detailed description about the market dynamics and trends including drivers, restraints and opportunities that have an influence on the current and future scenario of this market. This section also covers market attractiveness analysis and Porter’s five forces analysis to give an understanding about the competitive scenario of the global hemoglobin A1C testing devices market. Heat map Analysis is also provided for hemoglobin A1c testing devices market to explain the presence of the different market players in diverse market segments. All these factors will help the market players and new entrants in planning their strategies for future and for strengthening their position in the global market.
The global hemoglobin A1c testing devices market is analyzed on the basis of technologies and end-uses of hemoglobin A1c testing devices. With respect to technologies, this study considers five testing categories, namely immunoassays, ion-exchange high performance liquid chromatography (HPLC), direct enzymatic assay, boronate affinity chromatography and others (micro-optical detection method and capillary electrophoresis). Based on the end-uses, this market is categorized into laboratory testing and point-of-care (POC) testing segments. The above segments are analyzed on the basis of their market size (revenue) for the period 2011 to 2019 in terms of USD million, along with their growth forecast in terms of compounded annual growth rate (CAGR) % for the forecast period 2013 to 2019, considering 2012 as the base year.
With respect to geographical markets, the global hemoglobin A1C testing devices market has been classified into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). This section of report provides market size (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each regional market for hemoglobin A1C testing devices market in terms of USD million. The section also includes the CAGR % for every region for the given forecast period, considering 2012 as the base year.
The report further provides a list of strategic recommendations, which would be helpful for the current market players and the new entrants to grow in the hemoglobin A1c testing devices market. This report concludes with the company profiles section that includes key information such as company overview, financial overview, product portfolio, strategies and recent developments about major market players. Some of the major companies profiled in this report include Abbott Laboratories, Alere, Inc., Arkray, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc. Chek Diagnostics, Danaher Corporation, EKF Diagnostics Holdings Plc, Menarini Group, F. Hoffmann-La Roche Ltd., Sebia, Tosoh Corporation, Trinity Biotech Plc and Siemens Healthcare.